TUBERCULOSIS-CONTROL POLICIES IN MAJOR METROPOLITAN HEALTH DEPARTMENTS IN THE UNITED-STATES .5. STANDARD OF PRACTICE IN 1992

被引:10
作者
LEFF, DR
LEFF, AR
机构
[1] UNIV CHICAGO, DEPT MED MC6076, DIV BIOL SCI, PULM & CRIT CARE MED SECT, CHICAGO, IL 60637 USA
[2] UNIV CHICAGO, DEPT PEDIAT, DIV BIOL SCI, CHICAGO, IL 60637 USA
[3] NORTHWESTERN UNIV, CTR URBAN AFFAIRS & POLICY RES, EVANSTON, IL USA
[4] NORTHWESTERN UNIV, MEDILL SCH JOURNALISM, EVANSTON, IL USA
来源
AMERICAN REVIEW OF RESPIRATORY DISEASE | 1993年 / 148卷 / 06期
关键词
D O I
10.1164/ajrccm/148.6_Pt_1.1530
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Since 1978, we have surveyed the 28 metropolitan health departments initially reporting > 250 cases of tuberculosis/yr to determine the standard of practice in the control of pulmonary tuberculosis and the factors affecting treatment policy. In this survey, results were compared with data obtained in 1978, 1980, 1984, and 1988. As in the previous years, all departments completed the survey. The predominant treatment regimen was 6 months of chemotherapy(64 +/- 1.33% of patients) involving isoniazid (I), rifampin (R), and pyrazinamide (Z). Estimated duration of treatment, which had decreased from 20.2 +/- 2.1 months in 1980 to 7.58 +/- 1.02 months in 1988, increased to 9.34 +/- 2.32 months in 1992 (p < 0.01). This was attributed to an increase in drug-resistant cases (17 of 25 programs) and to increased incidence of HIV infection during the previous 4 yr. In 1984, HIV infection was estimated to coincide with tuberculosis in 2.54% of all patients, 7.72% in 1988, and 17.42% in 1992. Several other major departures from prior perceived practices were reported. In 1980, 32.1% of all patients were hospitalized initially for tuberculosis treatment, and this number decreased progressively to 17.8% in 1988; in 1992, 34.2 +/- 1.32% of patients with tuberculosis were hospitalized for initial treatment. In 1988, no program reported regular use of alternative therapy to isoniazid for chemoprophylaxis; in 1992, 21 programs used alternative regimens (predominantly R-containing). In 1992, nine programs reported increased funds for treatment of tuberculosis (27.2 +/- 1.97% after inflation), whereas 16 reported a mean decrease of 14% after inflation. We find that tuberculosis treatment in the major metropolitan health departments in the United States consists predominantly of short-course chemotherapy utilizing I, R, and Z and that overall mortality is not reported to be greater because of initially drug-resistant organisms. However, HIV-associated disease now is a major etiologic factor in tuberculosis, and the number of hospitalizations has doubled in 4 yr. Despite diminished resources, incidence of hospitalization and duration of treatment have increased for the first time in 12 yr. In the absence of an increase in funds for treatment, we conclude that problems currently identified in tuberculosis control by major metropolitan health departments likely will be exacerbated in the immediate future.
引用
收藏
页码:1530 / 1536
页数:7
相关论文
共 26 条
[1]
ALBERT R K, 1978, American Review of Respiratory Disease, V117, P605
[2]
ALTMAN LK, 1992, NY TIMES 0211, pB6
[3]
BAILEY WC, 1973, AM REV RESPIR DIS, V107, P854
[4]
TUBERCULOSIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
BARNES, PF ;
BLOCH, AB ;
DAVIDSON, PT ;
SNIDER, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (23) :1644-1650
[5]
RESURGENT TUBERCULOSIS IN NEW-YORK-CITY - HUMAN-IMMUNODEFICIENCY-VIRUS, HOMELESSNESS, AND THE DECLINE OF TUBERCULOSIS-CONTROL PROGRAMS [J].
BRUDNEY, K ;
DOBKIN, J .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (04) :745-749
[6]
CHAISSON RE, 1989, AM REV RESPIR DIS, V139, P1
[7]
INCIDENCE AND NATURAL-HISTORY OF MYCOBACTERIUM-AVIUM COMPLEX INFECTIONS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE [J].
CHAISSON, RE ;
MOORE, RD ;
RICHMAN, DD ;
KERULY, J ;
CREAGH, T .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (02) :285-289
[8]
A 62-DOSE, 6-MONTH THERAPY FOR PULMONARY AND EXTRAPULMONARY TUBERCULOSIS - A TWICE-WEEKLY, DIRECTLY OBSERVED, AND COST-EFFECTIVE REGIMEN [J].
COHN, DL ;
CATLIN, BJ ;
PETERSON, KL ;
JUDSON, FN ;
SBARBARO, JA .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :407-415
[9]
USPHS TUBERCULOSIS SHORT-COURSE CHEMOTHERAPY TRIAL-21 - EFFECTIVENESS, TOXICITY, AND ACCEPTABILITY - THE REPORT OF FINAL RESULTS [J].
COMBS, DL ;
OBRIEN, RJ ;
GEITER, LJ .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :397-406
[10]
AN OUTBREAK OF TUBERCULOSIS WITH ACCELERATED PROGRESSION AMONG PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS - AN ANALYSIS USING RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS [J].
DALEY, CL ;
SMALL, PM ;
SCHECTER, GF ;
SCHOOLNIK, GK ;
MCADAM, RA ;
JACOBS, WR ;
HOPEWELL, PC .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (04) :231-235